Immunome, Inc. (NASDAQ:IMNM - Get Free Report) rose 8.7% during mid-day trading on Monday . The company traded as high as $12.60 and last traded at $12.60. Approximately 222,079 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 759,327 shares. The stock had previously closed at $11.59.
A number of brokerages recently commented on IMNM. Piper Sandler lowered their price objective on shares of Immunome from $27.00 to $23.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 13th. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has an average rating of "Buy" and an average price target of $29.00.
View Our Latest Stock Analysis on IMNM
The firm has a market cap of $769.24 million, a P/E ratio of -1.63 and a beta of 1.82. The company's 50 day moving average is $13.63 and its two-hundred day moving average is $13.99.
Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The firm had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. Research analysts predict that Immunome, Inc. will post -1.92 EPS for the current year.
In other news, insider Jack Higgins sold 3,524 shares of the company's stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the sale, the insider now directly owns 16,000 shares in the company, valued at approximately $222,880. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Immunome news, CFO Max Rosett sold 14,380 shares of the business's stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares of the company's stock, valued at approximately $760,090.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jack Higgins sold 3,524 shares of the firm's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares of the company's stock, valued at approximately $222,880. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.60% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new stake in shares of Immunome during the second quarter worth approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the 2nd quarter valued at $97,000. Arizona State Retirement System lifted its stake in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock valued at $131,000 after purchasing an additional 918 shares during the period. EntryPoint Capital LLC boosted its position in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company's stock worth $136,000 after purchasing an additional 5,466 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after purchasing an additional 4,129 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.